- Big Bank Phobia: Not Too Big to Fail
- Expect Your Health Care in Retirement to Hit $200,000
- Why Car Prices Vary From City To City
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- 5 Worst Home Renovation Projects
Article
Sarepta: Staying Long and Strong
Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.
09:25AM 04/25/13
Article
Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval
The exon-skipping drug technology is worth a lot more than just eteplirsen alone.
10:39AM 03/05/13
Article
Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013
Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.
07:30AM 12/20/12
Article
Still Bullish on BioMarin, Lexicon Pharma
TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.
11:28AM 11/07/12
Article
Sunshine Heart: A Promising Treatment for Heart Failure Patients
Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.
08:00AM 11/05/12
Article
Lexicon Pharma: Blockbuster Potential From A Diabetes Drug
Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.
06:10AM 10/16/12
Article
Biomarin: Four Clinical Trial Events to Watch Before Year End
TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.
07:03AM 09/25/12
Article
Nanosphere: A Low-Risk, High-Growth Diagnostic Stock
A hospital-based sepsis test is the launching pad for Nanosphere.
07:13AM 09/18/12
Article
How To Trade Peregrine Pharma For Profits
Biotech trader Dan Rosenblum shows how to trade a controversial stock even if you lack strong conviction.
10:39AM 09/11/12
« Back
Page 1 of 1
Next »